Valuation dashboard for Moderna, Inc. (MRNA) with P/E N/A, P/B 1.34, EV/EBITDA -20.01 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets.
Analysis Summary
Moderna, Inc. reported revenue of $1.94B in the most recent fiscal year, growing at a 5-year CAGR of 19.3%.
Trailing-twelve-month margins: gross margin 55.3%, operating margin -158.1%, net margin -145.2%.
At the current price of $155.42, MRNA has negative trailing earnings (P/E not meaningful) and an ROE of -39.20%. Market capitalisation stands at $61.7B, placing it among large-cap names.
Balance sheet quality for MRNA: current ratio of 3.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.34 |
| EV / EBITDA | -20.01 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-1.54 |
| vs Current Price | -101.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| BBIO | BridgeBio Pharma, Inc. | $13.4B | 35.1% | ||
| JAZZ | Jazz Pharmaceuticals plc | $15.5B | 15.84 | 3.17 | 21.4% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.2B | 29.72 | -56.6% | |
| EXEL | Exelixis, Inc. | $14.4B | 17.29 | 7.74 | |
| BMRN | BioMarin Pharmaceutical Inc. | $12.7B | 170.34 | 1.98 | 1.2% |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 30.18 | 86.81 | |
| CAI | Caris Life Sciences, Inc. | $8.0B | 85.99 | 15.29 | 18.8% |
Price
| Price | $155.42 |
| Market Cap | $61.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -39.20% |
| Return on Invested Capital | -39.16% |
| Return on Assets | -28.75% |
| Gross Margin | 55.35% |
| Operating Margin | -158.13% |
| Net Margin | -145.16% |
Related companies: BBIO · BMRN · CAI · EXEL · HALO · JAZZ · MDGL
Explore sector: Healthcare · Biotechnology
More sections of MRNA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks